Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move ... Novo picked up the new triple agonist, UBT251, from China-based United Biotechnology. The candidate, which is still in ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational triple receptor agonist in a deal worth up to $2bn. The candidate, UBT251, is a ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO ... Researchers believe the GLP-1 agonist market could triple over the next decade to over $150 billion. Where to invest $1,000 right now?

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Novo Nordisk has experienced a 50% drop due to potential ... to develop and commercialize their UBT 251, a triple antagonist which targets GLP-1, GIP and glucagon receptors. The drug has shown ...